The American Journal of Medicine
Volume 123, Issue 4, Supplement , Pages S4-S15 , April 2010

Case Studies of Lower Respiratory Tract Infections: Community-Acquired Pneumonia

  • Thomas M. File Jr., MD, MSc

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Thomas M. File, Jr., MD, MSc, Infectious Disease Service and Division of HIV Research, Summa Health System, 75 Arch Street, Suite 506, Akron, Ohio, 44304

References 

  1. Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–1754
  2. File TM. Community-acquired pneumonia. Lancet. 2003;362:1991–2001
  3. File TM, Tan JS. Pneumonia in older adults: reversing the trend. JAMA. 2005;294:2760–2763
  4. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Rep. 2008;1–20
  5. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1–120
  6. Marston BJ, Plouffe JF, File TM, et al. Community-Based Pneumonia Incidence Study Group Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med. 1997;157:1709–1718
  7. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140–2145
  8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America and the American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27–S72
  9. Aujesky D, Fine MJ. The pneumonia severity index: a decade after the initial derivation and validation. Clin Infect Dis. 2008;47(suppl 3):S133–S139
  10. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250
  11. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  12. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006;27:151–157
  13. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131:466–473
  14. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2004;39:165–169
  15. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis. 2003;36:286–292
  16. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752–760
  17. Kunimoto D, Long R. Tuberculosis: still overlooked as a cause of community-acquired pneumonia—how not to miss it. Respir Care Clin North Am. 2005;11:25–34
  18. Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis. 2006;10:510–515
  19. Counsell SR, Tan JS, Dittus RS. Unsuspected pulmonary tuberculosis in a community teaching hospital. Arch Intern Med. 1989;149:1274–1278
  20. Singh A. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. Clin Infect Dis. 2007;45:133–135
  21. Wang JY, Hsueh PR, Jan IS, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61:903–908
  22. Ang D, Hsu AA, Tan BH. Fluoroquinolones may delay the diagnosis of tuberculosis. Singapore Med J. 2006;47:747–751
  23. Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis. 2005;9:1215–1219
  24. Avnon LS, Jotkowitz A, Smoliakov A, Flusser D, Heimer D. Can the routine use of fluoroquinolones for community-acquired pneumonia delay the diagnosis of tuberculosis? (A salutary case of diagnostic delay in a pilgrim returning from Mecca). Eur J Intern Med. 2006;17:444–446
  25. Grupper M, Potasman I. Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case. Am J Med Sci. 2008;335:141–144
  26. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34:1607–1612
  27. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003;37:1448–1452
  28. Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis. 2009;48:1361–1363
  29. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother. 2005;56:1058–1062
  30. Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother. 2007;59:860–865
  31. Nathwani D, Morgan M, Masterton RG, et al. British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61:976–994
  32. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45:315–321
  33. Nguyen ET, Kanne JP, Hoang LM, et al. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: radiographic and computed tomography findings. J Thorac Imaging. 2008;23:13–19
  34. Diederen BM, Kluytmans JA. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect. 2006;52:157–168
  35. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40:100–107
  36. Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med. 2009;53:358–365
  37. Wargo KA, Eiland EH. Appropriate antimicrobial therapy for community-acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40:1376–1378
  38. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883–3886
  39. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(suppl 5):S378–S385
  40. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138–2144
  41. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44:1208–1215
  42. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416
  43. Barton M, Hawkes M, Moore D, et al. Writing Group of the Expert Panel of Canadian infectious Disease, Infection Prevention and Control, and Public Health Specialists Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: a perspective for Canadian health care practitioners [published correction appears in Can J Infect Dis Med Microbiol. 2006;17:396]. Can J Infect Dis Med Microbiol. 2006;17(suppl SC):4C–24C
  44. Conte JE, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46:1475–1480
  45. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008;47:21–33
  46. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007;45(suppl 3):S184–S190
  47. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 19, 2008; Barcelona, Spain. Oral presentation O75.
  48. Moellering RC, Miller LG, Cosgrove SE, File TM, Corey GR. Improving clinical practice: MRSA case studies. MRSA. 2009;2–23
  49. US Department of Health and Human Services. Pandemic flu. [HHS Website.] http://www.hhs.gov/pandemicflu/Accessed November 2, 2009
  50. File TM, Gross PA. Performance measurement in community-acquired pneumonia: consequences intended and unintended. Clin Infect Dis. 2007;44:942–944
  51. Medicare Quality Improvement Community. Measures: pneumonia. [MedQIC Website.] http://www.qualitynet.org/dcs/ContentServer?level3=Measures&c=MQParents&pagename=Medqic%2FMeasure%2FMeasuresHome&cid=1089815967023&parentName=TopicAccessed November 10, 2009

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(10)00097-5

doi: 10.1016/j.amjmed.2010.02.002

The American Journal of Medicine
Volume 123, Issue 4, Supplement , Pages S4-S15 , April 2010

Article Tools

* Image Usage & Resolution